Amgen taps research firm to reassess Tavneos data

Amgen has hired an independent research firm to review Tavneos data after U.S. regulators proposed withdrawing the drug from the market. The move signals an effort to defend the product’s clinical case amid regulatory pressure, but it also highlights meaningful downside risk for a key asset. The news is negative for Amgen sentiment and could pressure shares modestly if investor concern about Tavneos intensifies.

Analysis

Amgen has hired an independent research firm to review Tavneos data after U.S. regulators proposed withdrawing the drug from the market. The move signals an effort to defend the product’s clinical case amid regulatory pressure, but it also highlights meaningful downside risk for a key asset. The news is negative for Amgen sentiment and could pressure shares modestly if investor concern about Tavneos intensifies.